Management of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is anchored by three established, first-line immunomodulatory therapies, each with demonstrated efficacy in controlled trials:

• Intravenous Immunoglobulin (IVIG): This is a cornerstone therapy, administered slowly via infusion. It works by neutralizing pathogenic autoantibodies and modulating the immune system's attack on the myelin sheath. While highly effective and fast-acting, it requires hospital visits and is associated with significant resource utilization and high product costs, challenging long-term maintenance.

• Corticosteroids (e.g., Prednisone): These agents reduce inflammation and suppress the immune response. Although they are often effective and inexpensive, their long-term use is severely limited by a spectrum of serious side effects, including weight gain, osteoporosis, and diabetes, necessitating the use of second-line, steroid-sparing agents for maintenance therapy.

• Plasma Exchange (PLEX): This procedure physically removes the patient’s plasma, thus eliminating harmful autoantibodies. While effective, PLEX is labor-intensive, requires specialized equipment and trained personnel, and its effects are typically transient, necessitating frequent or intermittent sessions.

These constraints in tolerability, convenience, and cost drive the continuous search for new, less burdensome treatments in the CIDP Market, as detailed in therapeutic guidelines, such as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook.